BCBS Kansas

Does BCBS Kansas cover Mounjaro?

Quick answer · Type 2 Diabetes

BCBS Kansas covers Mounjaro for type 2 diabetes with prior authorization on Employer / Commercial Insurance and ACA Marketplace.

  • Employer / Commercial Insurance: Covered (preferred drug). A1C of 6.5% or higher
  • ACA Marketplace: Covered (preferred drug). A1C of 6.5% or higher

Last verified June 2, 2026. Policy effective May 11, 2026. Source: KS_GLP1_ProgSum.pdf. How we verify this data →

Check your card for your exact plan →

Mounjaro for Type 2 Diabetes

What BCBS Kansas requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered (preferred drug)

What you need to qualify

  • A1C of 6.5% or higher
  • Lab results confirming eligibility

Qualification pathways

You can qualify through any one of these.

Continuation of therapy

All of:

  • Diagnosis of type 2 diabetes
  • A1C >= 6.5% confirmed by lab test or medical records
  • Requested agent is eligible for continuation of therapy (Mounjaro is eligible)
  • Patient will NOT use requested agent in combination with a DPP-4 containing agent
  • Patient will NOT use requested agent in combination with another GLP-1 receptor agonist
  • Patient does NOT have any FDA labeled contraindications to the requested agent
  • Patient age is within FDA labeling OR there is support for use outside labeled age range

Plus any one of:

  • Patient has been treated with a preferred agent within the past 90 days (starting on samples is not approvable)
  • Prescriber states patient has been treated with a preferred agent within the past 90 days and is at risk if therapy with a preferred agent is discontinued

New therapy - metformin/insulin step therapy or exception

All of:

  • Diagnosis of type 2 diabetes
  • A1C >= 6.5% confirmed by lab test or medical records
  • Patient will NOT use requested agent in combination with a DPP-4 containing agent
  • Patient will NOT use requested agent in combination with another GLP-1 receptor agonist
  • Patient does NOT have any FDA labeled contraindications to the requested agent
  • Patient age is within FDA labeling OR there is support for use outside labeled age range

Plus any one of:

  • Tried and had an inadequate response to ONE prerequisite agent containing metformin or insulin
  • Intolerance or hypersensitivity to metformin or insulin
  • FDA labeled contraindication to BOTH metformin AND insulin

CV risk reduction pathway

All of:

  • Diagnosis of type 2 diabetes
  • A1C >= 6.5% confirmed by lab test or medical records
  • Patient has established cardiovascular disease (e.g., MI, stroke, revascularization, TIA, unstable angina, amputation, symptomatic or asymptomatic CAD) OR multiple cardiovascular risk factors (e.g., HTN, dyslipidemia, family history of CVD, smoking)
  • Requested agent will be used to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal MI, or non-fatal stroke)
  • Patient will NOT use requested agent in combination with a DPP-4 containing agent
  • Patient will NOT use requested agent in combination with another GLP-1 receptor agonist
  • Patient does NOT have any FDA labeled contraindications to the requested agent
  • Patient age is within FDA labeling OR there is support for use outside labeled age range

CKD pathway

All of:

  • Diagnosis of type 2 diabetes
  • A1C >= 6.5% confirmed by lab test or medical records
  • Patient has chronic kidney disease (CKD)
  • Requested agent will be used to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death
  • Patient will NOT use requested agent in combination with a DPP-4 containing agent
  • Patient will NOT use requested agent in combination with another GLP-1 receptor agonist
  • Patient does NOT have any FDA labeled contraindications to the requested agent
  • Patient age is within FDA labeling OR there is support for use outside labeled age range

MASH pathway

All of:

  • Diagnosis of type 2 diabetes
  • A1C >= 6.5% confirmed by lab test or medical records
  • Patient has diagnosis of noncirrhotic MASH with moderate to advanced liver fibrosis (stages F2 to F3)
  • Patient will NOT use requested agent in combination with a DPP-4 containing agent
  • Patient will NOT use requested agent in combination with another GLP-1 receptor agonist
  • Patient does NOT have any FDA labeled contraindications to the requested agent
  • Patient age is within FDA labeling OR there is support for use outside labeled age range

Documentation to bring

  • Documentation of type 2 diabetes diagnosis
  • Lab test results or medical records confirming A1C >= 6.5%
  • Documentation of prior preferred agent use within past 90 days (for continuation pathway)
  • Documentation of inadequate response to, intolerance of, hypersensitivity to, or contraindication to metformin or insulin (for new therapy pathway where applicable)
  • Documentation of established CVD or multiple CV risk factors if using CV pathway
  • Documentation of CKD diagnosis if using CKD pathway
  • Documentation of noncirrhotic MASH with F2-F3 fibrosis if using MASH pathway
  • Confirmation that patient will not use with DPP-4 containing agent
  • Confirmation that patient will not use with another GLP-1 receptor agonist

Quantity limits

  • 2.5 MG/0.5ML — 4 pens per 28 days
  • 5 MG/0.5ML, 7.5 MG/0.5ML, 10 MG/0.5ML, 12.5 MG/0.5ML, 15 MG/0.5ML — 4 pens per 28 days

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • To renew, the plan looks for Continuation of therapy is available if the patient has been treated with a preferred agent within the past 90 days (starting on samples is not approvable) OR the prescriber states the patient has been treated with a preferred agent within the past 90 days and is at risk if therapy with a preferred agent is discontinued.

Not covered when

  • Combination with DPP-4 containing agents not permitted
  • Combination with another GLP-1 receptor agonist not permitted
  • FDA labeled contraindications to the requested agent
  • Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Prior serious hypersensitivity reaction to tirzepatide or product components

Policy note: Mounjaro is listed as a preferred agent. The 2.5 mg/0.5 mL strength has a 180-day duration limit noted in the QL table (likely titration dose). Non-preferred agents (Byetta, Victoza) require trial of TWO preferred agents before approval. Fill limit of one GLP-1 agent and one strength per 28 days applies. Pediatric patients aged 10 years and older are included per FDA labeling.

Policy effective May 11, 2026 · verified June 2, 2026 · source: KS_GLP1_ProgSum.pdf

ACA Marketplace

Covered (preferred drug)

What you need to qualify

  • A1C of 6.5% or higher
  • Lab results confirming eligibility

Qualification pathways

You can qualify through any one of these.

Continuation of therapy

All of:

  • Diagnosis of type 2 diabetes
  • A1C >= 6.5% confirmed by lab test or medical records
  • Requested agent is eligible for continuation of therapy (Mounjaro is eligible)
  • Patient will NOT use requested agent in combination with a DPP-4 containing agent
  • Patient will NOT use requested agent in combination with another GLP-1 receptor agonist
  • Patient does NOT have any FDA labeled contraindications to the requested agent
  • Patient age is within FDA labeling OR there is support for use outside labeled age range

Plus any one of:

  • Patient has been treated with a preferred agent within the past 90 days (starting on samples is not approvable)
  • Prescriber states patient has been treated with a preferred agent within the past 90 days and is at risk if therapy with a preferred agent is discontinued

New therapy - metformin/insulin step therapy or exception

All of:

  • Diagnosis of type 2 diabetes
  • A1C >= 6.5% confirmed by lab test or medical records
  • Patient will NOT use requested agent in combination with a DPP-4 containing agent
  • Patient will NOT use requested agent in combination with another GLP-1 receptor agonist
  • Patient does NOT have any FDA labeled contraindications to the requested agent
  • Patient age is within FDA labeling OR there is support for use outside labeled age range

Plus any one of:

  • Tried and had an inadequate response to ONE prerequisite agent containing metformin or insulin
  • Intolerance or hypersensitivity to metformin or insulin
  • FDA labeled contraindication to BOTH metformin AND insulin

CV risk reduction pathway

All of:

  • Diagnosis of type 2 diabetes
  • A1C >= 6.5% confirmed by lab test or medical records
  • Patient has established cardiovascular disease (e.g., MI, stroke, revascularization, TIA, unstable angina, amputation, symptomatic or asymptomatic CAD) OR multiple cardiovascular risk factors (e.g., HTN, dyslipidemia, family history of CVD, smoking)
  • Requested agent will be used to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal MI, or non-fatal stroke)
  • Patient will NOT use requested agent in combination with a DPP-4 containing agent
  • Patient will NOT use requested agent in combination with another GLP-1 receptor agonist
  • Patient does NOT have any FDA labeled contraindications to the requested agent
  • Patient age is within FDA labeling OR there is support for use outside labeled age range

CKD pathway

All of:

  • Diagnosis of type 2 diabetes
  • A1C >= 6.5% confirmed by lab test or medical records
  • Patient has chronic kidney disease (CKD)
  • Requested agent will be used to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death
  • Patient will NOT use requested agent in combination with a DPP-4 containing agent
  • Patient will NOT use requested agent in combination with another GLP-1 receptor agonist
  • Patient does NOT have any FDA labeled contraindications to the requested agent
  • Patient age is within FDA labeling OR there is support for use outside labeled age range

MASH pathway

All of:

  • Diagnosis of type 2 diabetes
  • A1C >= 6.5% confirmed by lab test or medical records
  • Patient has diagnosis of noncirrhotic MASH with moderate to advanced liver fibrosis (stages F2 to F3)
  • Patient will NOT use requested agent in combination with a DPP-4 containing agent
  • Patient will NOT use requested agent in combination with another GLP-1 receptor agonist
  • Patient does NOT have any FDA labeled contraindications to the requested agent
  • Patient age is within FDA labeling OR there is support for use outside labeled age range

Documentation to bring

  • Documentation of type 2 diabetes diagnosis
  • Lab test results or medical records confirming A1C >= 6.5%
  • Documentation of prior preferred agent use within past 90 days (for continuation pathway)
  • Documentation of inadequate response to, intolerance of, hypersensitivity to, or contraindication to metformin or insulin (for new therapy pathway where applicable)
  • Documentation of established CVD or multiple CV risk factors if using CV pathway
  • Documentation of CKD diagnosis if using CKD pathway
  • Documentation of noncirrhotic MASH with F2-F3 fibrosis if using MASH pathway
  • Confirmation that patient will not use with DPP-4 containing agent
  • Confirmation that patient will not use with another GLP-1 receptor agonist

Quantity limits

  • 2.5 MG/0.5ML — 4 pens per 28 days
  • 5 MG/0.5ML, 7.5 MG/0.5ML, 10 MG/0.5ML, 12.5 MG/0.5ML, 15 MG/0.5ML — 4 pens per 28 days

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • To renew, the plan looks for Continuation of therapy is available if the patient has been treated with a preferred agent within the past 90 days (starting on samples is not approvable) OR the prescriber states the patient has been treated with a preferred agent within the past 90 days and is at risk if therapy with a preferred agent is discontinued.

Not covered when

  • Combination with DPP-4 containing agents not permitted
  • Combination with another GLP-1 receptor agonist not permitted
  • FDA labeled contraindications to the requested agent
  • Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Prior serious hypersensitivity reaction to tirzepatide or product components

Policy note: Mounjaro is listed as a preferred agent. The 2.5 mg/0.5 mL strength has a 180-day duration limit noted in the QL table (likely titration dose). Non-preferred agents (Byetta, Victoza) require trial of TWO preferred agents before approval. Fill limit of one GLP-1 agent and one strength per 28 days applies. Pediatric patients aged 10 years and older are included per FDA labeling.

Policy effective May 11, 2026 · verified June 2, 2026 · source: KS_GLP1_ProgSum.pdf

Why Mounjaro requests get denied by BCBS Kansas

Based on what this policy asks for. Fix these before the first submission.

  1. Wrong brand for the diagnosis. Mounjaro and Zepbound are the same molecule with different approved uses; a request for Mounjaro under a diagnosis that matches Zepbound is routinely denied.
  2. No recent A1C result on file.

Frequently asked questions

Does BCBS Kansas cover Mounjaro?
BCBS Kansas covers Mounjaro for type 2 diabetes with prior authorization on Employer / Commercial Insurance and ACA Marketplace.
How long does a Mounjaro approval last with BCBS Kansas?
Initial approvals last 12 months, and renewals are granted in 12-month periods.
What does BCBS Kansas require to renew Mounjaro?
Continuation of therapy is available if the patient has been treated with a preferred agent within the past 90 days (starting on samples is not approvable) OR the prescriber states the patient has been treated with a preferred agent within the past 90 days and is at risk if therapy with a preferred agent is discontinued.
How current is this information?
This page reflects BCBS Kansas's written policy as of May 11, 2026, last verified against the source document on June 2, 2026.

Other medications under BCBS Kansas

Mounjaro coverage under other plans

All insurance plans · All medications

This page summarizes BCBS Kansas's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.